JP2004504376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004504376A5 JP2004504376A5 JP2002514087A JP2002514087A JP2004504376A5 JP 2004504376 A5 JP2004504376 A5 JP 2004504376A5 JP 2002514087 A JP2002514087 A JP 2002514087A JP 2002514087 A JP2002514087 A JP 2002514087A JP 2004504376 A5 JP2004504376 A5 JP 2004504376A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- ht2c
- pharmaceutical composition
- antagonist
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 10
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 9
- 239000000018 receptor agonist Substances 0.000 description 7
- 229940044601 receptor agonist Drugs 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 108091005435 5-HT6 receptors Proteins 0.000 description 5
- 239000003751 serotonin 6 antagonist Substances 0.000 description 5
- 229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 101150104779 HTR2A gene Proteins 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 235000014632 disordered eating Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 101150075901 htr2 gene Proteins 0.000 description 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 1
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 1
- 102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 1
- PBIZLLBVGQBNJU-UHFFFAOYSA-N C1CC2=NC=CC=CC2=C2C1CCN2 Chemical class C1CC2=NC=CC=CC2=C2C1CCN2 PBIZLLBVGQBNJU-UHFFFAOYSA-N 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- -1 piperazinylpyrazine compound Chemical class 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- ISZIQZCZKOFSBT-UHFFFAOYSA-N pyrrolo[2,3-g][1]benzazepine Chemical group N1=CC=CC=C2C3=NC=CC3=CC=C21 ISZIQZCZKOFSBT-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0002754A SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | New pharmaceutical combination formulation and method of treatment with the combination |
| PCT/SE2001/001651 WO2002008178A1 (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004504376A JP2004504376A (ja) | 2004-02-12 |
| JP2004504376A5 true JP2004504376A5 (zh) | 2008-07-17 |
Family
ID=20280577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002514087A Withdrawn JP2004504376A (ja) | 2000-07-21 | 2001-07-19 | 医薬製剤としてのセロトニンアゴニスト（５ｈｔ２）とアンタゴニスト（５ｈｔ６）の新規組み合わせ |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1301476A1 (zh) |
| JP (1) | JP2004504376A (zh) |
| KR (1) | KR100845450B1 (zh) |
| CN (1) | CN1221254C (zh) |
| AU (2) | AU8273401A (zh) |
| BR (1) | BR0112661A (zh) |
| CA (1) | CA2411192A1 (zh) |
| EA (1) | EA006604B1 (zh) |
| HK (1) | HK1057536A1 (zh) |
| HU (1) | HUP0301346A3 (zh) |
| IL (1) | IL154057A0 (zh) |
| MX (1) | MXPA03000548A (zh) |
| NO (1) | NO20030304L (zh) |
| NZ (1) | NZ523216A (zh) |
| PL (1) | PL360309A1 (zh) |
| SE (1) | SE0002754D0 (zh) |
| WO (1) | WO2002008178A1 (zh) |
| YU (1) | YU2603A (zh) |
| ZA (1) | ZA200210234B (zh) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
| EA006205B1 (ru) * | 2000-11-02 | 2005-10-27 | Уайт | 1-арил- или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6 |
| ES2268113T3 (es) | 2001-06-15 | 2007-03-16 | F. Hoffmann-La Roche Ag | Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6. |
| CN1321110C (zh) * | 2001-06-15 | 2007-06-13 | 弗·哈夫曼-拉罗切有限公司 | 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物 |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| JP4455064B2 (ja) | 2002-03-27 | 2010-04-21 | グラクソ グループ リミテッド | キノリン誘導体および５−ｈｔ６リガンドとしてのその使用 |
| CL2004000826A1 (es) * | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| ATE313532T1 (de) | 2003-07-22 | 2006-01-15 | Arena Pharm Inc | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
| EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| US20100048713A1 (en) * | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| US20070293475A1 (en) * | 2006-06-20 | 2007-12-20 | Alcon Manufacturing Ltd. | Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma |
| DE602007012080D1 (de) * | 2007-08-01 | 2011-03-03 | Esteve Labor Dr | Kombination von mindestens zwei 5-HT6-Liganden |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| WO2009074607A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| UA100192C2 (en) | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
| MY157497A (en) | 2009-06-15 | 2016-06-15 | Takeda Pharmaceutical | Pyrazinooxazepine derivatives |
| JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| CN108472285A (zh) | 2015-07-15 | 2018-08-31 | 阿速万科学有限责任公司 | 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物 |
| CN107628981B (zh) * | 2017-10-31 | 2019-07-30 | 威海市妇女儿童医院 | 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用 |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| CN111269165A (zh) * | 2018-12-05 | 2020-06-12 | 中国科学院大连化学物理研究所 | 一种3-芳基磺酰基吲哚衍生物的合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
| GB9819035D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
-
2000
- 2000-07-21 SE SE0002754A patent/SE0002754D0/xx unknown
-
2001
- 2001-07-19 AU AU8273401A patent/AU8273401A/xx active Pending
- 2001-07-19 KR KR1020037000321A patent/KR100845450B1/ko not_active IP Right Cessation
- 2001-07-19 WO PCT/SE2001/001651 patent/WO2002008178A1/en active IP Right Grant
- 2001-07-19 HU HU0301346A patent/HUP0301346A3/hu unknown
- 2001-07-19 EP EP01961472A patent/EP1301476A1/en not_active Withdrawn
- 2001-07-19 CN CNB018131549A patent/CN1221254C/zh not_active Expired - Fee Related
- 2001-07-19 PL PL36030901A patent/PL360309A1/xx not_active Application Discontinuation
- 2001-07-19 CA CA002411192A patent/CA2411192A1/en not_active Abandoned
- 2001-07-19 NZ NZ523216A patent/NZ523216A/en not_active IP Right Cessation
- 2001-07-19 JP JP2002514087A patent/JP2004504376A/ja not_active Withdrawn
- 2001-07-19 MX MXPA03000548A patent/MXPA03000548A/es active IP Right Grant
- 2001-07-19 AU AU2001282734A patent/AU2001282734B2/en not_active Ceased
- 2001-07-19 YU YU2603A patent/YU2603A/sh unknown
- 2001-07-19 IL IL15405701A patent/IL154057A0/xx unknown
- 2001-07-19 EA EA200300183A patent/EA006604B1/ru not_active IP Right Cessation
- 2001-07-19 BR BR0112661-0A patent/BR0112661A/pt not_active IP Right Cessation
-
2002
- 2002-12-18 ZA ZA200210234A patent/ZA200210234B/en unknown
-
2003
- 2003-01-20 NO NO20030304A patent/NO20030304L/no not_active Application Discontinuation
-
2004
- 2004-01-15 HK HK04100306A patent/HK1057536A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004504376A5 (zh) | ||
| AU2006252051B2 (en) | Orodispersible Pharmaceutical Composition for Oromucosal or Sublingual Administration of Agomelatine | |
| HUP0301346A2 (hu) | Szterotonin agonista (5HT2) és antagonista (5HT6) új kombinációja gyógyászati készítményként és eljárás az előállítására | |
| CA2229597A1 (en) | Oral fast-dissolving compositions for dopamine agonists | |
| AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
| RU2005124363A (ru) | Твердые пероральные дозируемые формы валсартана | |
| WO2000064441A3 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
| JP2008531714A (ja) | 不安障害の治療用及び／又は予防用の医薬組成物 | |
| JP2002515435A (ja) | 鬱病処置のための組合せ治療 | |
| JP2007145875A5 (zh) | ||
| AR035603A1 (es) | Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos | |
| SE0102036D0 (sv) | Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof | |
| PL201685B1 (pl) | Zastosowanie N-piperydyno-5-(4-chlorofenylo)-1-(2,4-dichlorofenylo)-4-metylopirazolo-3-karboksyamidu do wytwarzania leków | |
| JP2009541443A5 (zh) | ||
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| JP2008518896A (ja) | ニコチン性アセチルコリンα７受容体アンタゴニストの組合せ剤 | |
| WO2005092307A3 (en) | Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists | |
| EP2301625A3 (en) | Compositions and methods for treating cognitive disorders | |
| JP2002535370A5 (zh) | ||
| JP2004529117A5 (zh) | ||
| CA2483002A1 (en) | New pharmaceutical composition | |
| EP1623741A2 (en) | Cannabinoid receptor ligands for hair growth modulation | |
| WO2005011595A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease | |
| NL8002041A (nl) | Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel. | |
| CA2534833A1 (en) | Bicyclo[3.1.1]heptane substituted benzimidazolone and quinazoli-none derivatives as agonists on human orl1 receptors |